microRNA-based predictor for diagnosis of frontotemporal dementia.

IF 4 2区医学 Q1 CLINICAL NEUROLOGY

Neuropathology and Applied Neurobiology Pub Date : 2023-08-01 DOI:10.1111/nan.12916

Iddo Magen, Nancy-Sarah Yacovzada, Jason D Warren, Carolin Heller, Imogen Swift, Yoana Bobeva, Andrea Malaspina, Jonathan D Rohrer, Pietro Fratta, Eran Hornstein

{"title":"microRNA-based predictor for diagnosis of frontotemporal dementia.","authors":"Iddo Magen, Nancy-Sarah Yacovzada, Jason D Warren, Carolin Heller, Imogen Swift, Yoana Bobeva, Andrea Malaspina, Jonathan D Rohrer, Pietro Fratta, Eran Hornstein","doi":"10.1111/nan.12916","DOIUrl":null,"url":null,"abstract":"Aims: This study aimed to explore the non-linear relationships between cell-free microRNAs (miRNAs) and their contribution to prediction of Frontotemporal dementia (FTD), an early onset dementia that is clinically heterogeneous, and too often suffers from delayed diagnosis.Methods: We initially studied a training cohort of 219 subjects (135 FTD and 84 non-neurodegenerative controls) and then validated the results in a cohort of 74 subjects (33 FTD and 41 controls).Results: On the basis of cell-free plasma miRNA profiling by next generation sequencing and machine learning approaches, we develop a non-linear prediction model that accurately distinguishes FTD from non-neurodegenerative controls in ~90% of cases.Conclusions: The fascinating potential of diagnostic miRNA biomarkers might enable early-stage detection and a cost-effective screening approach for clinical trials that can facilitate drug development.","PeriodicalId":19151,"journal":{"name":"Neuropathology and Applied Neurobiology","volume":"49 4","pages":"e12916"},"PeriodicalIF":4.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropathology and Applied Neurobiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/nan.12916","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aims: This study aimed to explore the non-linear relationships between cell-free microRNAs (miRNAs) and their contribution to prediction of Frontotemporal dementia (FTD), an early onset dementia that is clinically heterogeneous, and too often suffers from delayed diagnosis.

Methods: We initially studied a training cohort of 219 subjects (135 FTD and 84 non-neurodegenerative controls) and then validated the results in a cohort of 74 subjects (33 FTD and 41 controls).

Results: On the basis of cell-free plasma miRNA profiling by next generation sequencing and machine learning approaches, we develop a non-linear prediction model that accurately distinguishes FTD from non-neurodegenerative controls in ~90% of cases.

Conclusions: The fascinating potential of diagnostic miRNA biomarkers might enable early-stage detection and a cost-effective screening approach for clinical trials that can facilitate drug development.

查看原文本刊更多论文

基于 microRNA 的额颞叶痴呆症诊断预测因子

目的：本研究旨在探索无细胞microRNAs（miRNAs）之间的非线性关系及其对预测额颞叶痴呆症（FTD）的贡献：我们首先研究了由 219 名受试者（135 名 FTD 受试者和 84 名非神经退行性疾病对照组受试者）组成的训练队列，然后在由 74 名受试者（33 名 FTD 受试者和 41 名对照组受试者）组成的队列中验证了研究结果：在新一代测序技术和机器学习方法对无细胞血浆 miRNA 进行分析的基础上，我们建立了一个非线性预测模型，该模型能在约 90% 的病例中准确区分 FTD 和非神经退行性疾病对照组：诊断性 miRNA 生物标记物的巨大潜力可实现早期检测，并为临床试验提供具有成本效益的筛选方法，从而促进药物开发。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuropathology and Applied Neurobiology 医学-病理学

CiteScore

8.20

自引率

2.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Neuropathology and Applied Neurobiology is an international journal for the publication of original papers, both clinical and experimental, on problems and pathological processes in neuropathology and muscle disease. Established in 1974, this reputable and well respected journal is an international journal sponsored by the British Neuropathological Society, one of the world leading societies for Neuropathology, pioneering research and scientific endeavour with a global membership base. Additionally members of the British Neuropathological Society get 50% off the cost of print colour on acceptance of their article.